Study supports the effectiveness of Eylea

Bayer has announced study results that support the efficacy of proactive treat-and-extend dosing regimens with aflibercept solution for intravitreal injection in patients with wet age-related macular degeneration (AMD).

The treat-and-extend treatment approach was already proven to be effective in wet AMD in the Altair study. In the Aries study, a proactive treat-and-extend regimen with aflibercept led to excellent visual acuity gains.

Dr Jackie Napier, medical director of ophthalmology at Bayer, said: ‘The results are important as they reconfirm the existing evidence for proactive treat-and-extend regimen with aflibercept and offer clinicians the possibility of minimising the number of injections that need to be administered for sight-saving treatment.’